Tag: Keytruda

December 17, 2020 Off

Merck’s supplemental BLA in priority review for Keytruda chemotherapy combo

By BusinessWire

The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction